For the year ending 2025-12-31, BDSX had -$7,257K decrease in cash & cash equivalents over the period. -$23,530K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues | 88,499 |
| Direct costs and expenses (less employee related expenses and depreciation and amortization) | 12,072 |
| Employee related expenses (less share-based compensation expenses) | 66,824 |
| Contracted services expenses | 7,012 |
| Sales and marketing education and event expenses | 7,562 |
| Occupancy and equipment service expenses | 4,077 |
| Clinical trials and associated costs | 1,730 |
| Depreciation and amortization expense | 5,670 |
| Share-based compensation expenses | 4,139 |
| Interest expense | 7,716 |
| Change in fair value of warrant liability, net | 280 |
| Other segment items | 6,682 |
| Net loss | -35,265 |
| Depreciation and amortization | 5,670 |
| Accretion of lease right-of-use assets | -69 |
| Share-based compensation expense | 4,139 |
| Change in fair value of warrant liability, net | 280 |
| Provision for credit losses | 180 |
| Accrued interest, amortization of debt issuance costs and other | 1,304 |
| Inventory excess and obsolescence | 49 |
| Impairment loss on intangible assets | 107 |
| Accounts receivable | 531 |
| Other current assets | 258 |
| Other long-term assets | 121 |
| Accounts payable and other accrued liabilities | 1,859 |
| Deferred revenue | 174 |
| Current and long-term operating lease liabilities | -789 |
| Net cash, cash equivalents, and restricted cash used in operating activities | -23,271 |
| Purchase of property and equipment | 259 |
| Patent costs and intangible asset acquisition, net | 144 |
| Net cash, cash equivalents, and restricted cash used in investing activities | -403 |
| Proceeds from the issuance of common stock | 7,320 |
| Proceeds from issuance of common stock under employee stock purchase plan | 497 |
| Proceeds from term loan and notes payable | 10,000 |
| Repayment of term loan and notes payable | 21 |
| Payment of debt issuance costs | 30 |
| Equity financing costs | 532 |
| Other | -817 |
| Net cash, cash equivalents, and restricted cash provided by financing activities | 16,417 |
| Net decrease in cash, cash equivalents, and restricted cash | -7,257 |
| Cash, cash equivalents, and restricted cash beginning of period | 26,332 |
| Cash, cash equivalents, and restricted cash end of period | 19,075 |
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)